Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · May 15, 2023

Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis

The British Journal of Dermatology


Additional Info

The British Journal of Dermatology
Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials
Br J Dermatol 2023 Mar 30;[EPub Ahead of Print], A Blauvelt, JP Thyssen, E Guttman-Yassky, T Bieber, E Serra-Baldrich, E Simpson, D Rosmarin, H Elmaraghy, E Meskimen, CR Natalie, Z Liu, C Xu, E Pierce, M Morgan-Cox, E Garcia Gil, JI Silverberg

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading